Program Area: Therapeutics Threat Area: COVID-1
Post# of 157722
(Total Views: 473)
Posted On: 06/03/2024 9:49:14 AM
Re: Boatbuilder #144150
Program Area: Therapeutics
Threat Area: COVID-19
Description:
Regeneron is developing a monoclonal antibody (mAb) therapeutic candidate for pre-exposure prophylaxis (PrEP) designed to neutralize all circulating virus variants, including recent Omicron subvariants. The investigational mAb binds to a conserved region of the virus, thus decreasing the risk of losing activity as the virus evolves over time and has a half-life extension to provide long-acting prevention.
Look at how much money they are throwing at this.
“Unique Impact:
Pre-exposure prophylaxis (PrEP) is a therapeutic option for preventing infection in individuals who are immune compromised or who are not protected adequately by vaccination. Currently there are no U.S. Food and Drug Administration (FDA)-approved PrEP therapeutics for COVID-19, meaning novel monoclonal antibodies could fill a critical gap in protecting individuals at high risk for COVID-19 complications.
Base Award Amount: $326,475,498.00 (August 22, 2023)
Cost Share: Yes”
https://medicalcountermeasures.gov/nextgen
Threat Area: COVID-19
Description:
Regeneron is developing a monoclonal antibody (mAb) therapeutic candidate for pre-exposure prophylaxis (PrEP) designed to neutralize all circulating virus variants, including recent Omicron subvariants. The investigational mAb binds to a conserved region of the virus, thus decreasing the risk of losing activity as the virus evolves over time and has a half-life extension to provide long-acting prevention.
Look at how much money they are throwing at this.
“Unique Impact:
Pre-exposure prophylaxis (PrEP) is a therapeutic option for preventing infection in individuals who are immune compromised or who are not protected adequately by vaccination. Currently there are no U.S. Food and Drug Administration (FDA)-approved PrEP therapeutics for COVID-19, meaning novel monoclonal antibodies could fill a critical gap in protecting individuals at high risk for COVID-19 complications.
Base Award Amount: $326,475,498.00 (August 22, 2023)
Cost Share: Yes”
https://medicalcountermeasures.gov/nextgen
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
— Jeremiah 51:36